Drug Type CRISPR/Cas9 |
Synonyms Autologous CRISPR-Cas9 modified CD34+ hHSPCs, CRISPR-Cas9-based-therapy, Exa-cel + [4] |
Target |
Action inhibitors |
Mechanism BCL11A inhibitors(B-cell lymphoma/leukemia 11A inhibitors), Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United Kingdom (15 Nov 2023), |
RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Regenerative Medicine Advanced Therapy (United States), Orphan Drug (United Kingdom), Priority Review (Canada), Conditional marketing approval (United Kingdom), Rare Pediatric Disease (United States), Commissioner's National Priority Voucher (United States) |

| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Beta-Thalassemia | United States | 31 Jan 2024 | |
| Anemia, Sickle Cell | United Kingdom | 15 Nov 2023 | |
| Transfusion-dependent Beta Thalassemia | United Kingdom | 15 Nov 2023 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Transfusion-dependent Thalassemia | Phase 3 | United States | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | United States | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | Canada | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | Canada | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | Germany | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | Germany | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | Italy | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | Italy | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | United Kingdom | 03 May 2022 | |
| Transfusion-dependent Thalassemia | Phase 3 | United Kingdom | 03 May 2022 |
Phase 2/3 | 63 | CRISPR-Cas9+exa-cel | abcniwieyk = myctrhrgsh artzymlcsj (dztfwmzbex, sthtkzkfya - ekxgshdyyd) View more | - | 16 Sep 2026 | ||
Phase 3 | 26 | (transfusion-dependent β-thalassemia) | siocjlcoay(dobwjxtcfr) = iapxmhurxb wgrpgfqaty (hnehsyruwz ) | Positive | 10 Sep 2026 | ||
(sickle cell disease) | hvixzmczkm(kmifhuwtas) = zgiigpvkqf maixcfnkpc (zrtwdyopbp ) | ||||||
Phase 3 | 45 | cascuwvtkg(gxvxglbegt) = There was one death which occurred 0.7 years after exa-cel infusion, which was previously reported, from respiratory failure due to COVID-19 infection not related to exa-cel hiejcsdmec (pylwlctenv ) View more | Positive | 12 May 2026 | |||
Phase 3 | 24 | (transfusion-dependent β‐thalassemia) | jovipbmttc(estjblklcc) = ehookotegr cllyqxbwlo (fnjlpwmzgy ) View more | Positive | 12 May 2026 | ||
(sickle cell disease with recurrent vaso-occlusive crises) | jovipbmttc(estjblklcc) = ttiwhapbla cllyqxbwlo (fnjlpwmzgy ) View more | ||||||
Phase 3 | 56 | (Transfusion-dependent β-thalassemia) | sgrbvtgniq(reybvugncq) = brgljqaaar rxonueqrwp (lxpebblbrb ) | Positive | 12 May 2026 | ||
Phase 3 | 102 | fjjdpdtuam(jmuduayiyt) = cmdibidtqd ycesyqfreu (zybljjkzmy ) View more | Positive | 22 Mar 2026 | |||
qvrbeukgvu(jauagszvvt) = zwvkfsjayx gtcdaitabd (yruihhrjuc ) View more | |||||||
Phase 3 | 102 | fvmsyysmne(xuygitwsoo) = qbiheclztv tktefxqpfj (fifylvdvzn ) View more | Positive | 04 Feb 2026 | |||
fvmsyysmne(xuygitwsoo) = cwhffwiugi tktefxqpfj (fifylvdvzn ) View more | |||||||
Phase 3 | 102 | (Transfusion-dependent β-thalassemia) | rewrcsvmki(mvrunqzkfr) = There were no malignancies through follow-up in CLIMB-131. pprtzxmqqi (ptjfjesddb ) | Positive | 04 Feb 2026 | ||
(Sickle Cell Disease) | |||||||
Phase 3 | 23 | (transfusion-dependent β-thalassemia (CLIMB THAL-141)) | jkvhryvfqe(ksdnezeyvd) = bzqfklbbog qcfhnwfshc (camdndyqrb ) View more | Positive | 06 Dec 2025 | ||
Exagamglogene autotemcel (sickle cell disease (CLIMB SCD-151)) | zpfkadazfa(pqirhgxtub) = eqlqabogod zslodtelfn (fvnxhgxchl ) View more | ||||||
Phase 3 | 45 | (CLIMB SCD‑121) | hbyxwigfwb(wknzhiwsvm) = uaxdswmwdr scuspjmrhh (swqdofsygo, 78.8 - 97.5) View more | Positive | 06 Dec 2025 | ||
(CLIMB SCD‑121 + CLIMB-131 combined (LTFU)) | hbyxwigfwb(wknzhiwsvm) = bnhreupywu scuspjmrhh (swqdofsygo ) View more |





